

BRAINSTORM CELL THERAPEUTICS INC.

Form 8-K

December 09, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 5, 2016

**Brainstorm Cell Therapeutics Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction of incorporation)*

**001-36641**

*(Commission File No.)*

**20-7273918**

*(IRS Employer Identification No.)*

**3 University Plaza Drive, Suite 320**

**Hackensack, NJ**

*(Address of principal executive offices)*

**07601**

*(Zip Code)*

**(201) 488-0460**

*(Registrant's telephone number, including area code)*

N/A

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 8-K

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On December 9, 2016, at 3:05 p.m. Greenwich Mean Time, James D. Berry, MD, MPH of the Department of Neurology at Massachusetts General Hospital, will present clinical data from Brainstorm Cell Therapeutics Inc.'s (the "Company") NurOwn® Phase 2 Trial, at the 27<sup>th</sup> International Symposium on ALS/MND. Notice of this event was previously given on December 5, 2016 via press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K.

The slides that will be used for the presentation will be posted on the Company's website ([www.brainstorm-cell.com](http://www.brainstorm-cell.com)) prior to the conference call. A copy of the slides is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits.*

**Exhibit No. Description**

|      |  |
|------|--|
| 99.1 | Press Release dated December 5, 2016       |
| 99.2 | Presentation slides dated December 9, 2016 |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 9, 2016 Brainstorm Cell Therapeutics Inc.

By: /s/ Chaim Lebovits  
Chaim Lebovits  
Chief Executive Officer and President